Literature DB >> 17999257

Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders.

Srinivasan Tirupati1, Ling-Ern Chua.   

Abstract

OBJECTIVE: The aim of this paper was to identify a simple screening measure for detecting metabolic syndrome (MetS) in people with schizophrenia and schizoaffective disorders.
METHOD: A total of 202 patients with chronic schizophrenia and schizoaffective disorders on antipsychotic medications were assessed for MetS using the criteria defined by the International Diabetes Federation. Receiver operating characteristic (ROC) analysis was applied using body mass index (BMI) as the test variable for diagnosis of MetS.
RESULTS: The prevalence of MetS was 69.3%. Logistic regression analysis identified BMI and gender as significant predictors of MetS. ROC analysis identified BMI >28.7 as the criterion value with highest accuracy in terms of specificity and sensitivity. The likelihood ratios were robust at this cut-off score. The area under the curve was 0.75.
CONCLUSION: BMI is a quick and easy measure, and can be used as a screening test for MetS in any clinical or community setting.

Entities:  

Mesh:

Year:  2007        PMID: 17999257     DOI: 10.1080/10398560701636906

Source DB:  PubMed          Journal:  Australas Psychiatry        ISSN: 1039-8562            Impact factor:   1.369


  6 in total

1.  Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis.

Authors:  Stefan Busse; Hans-Gert Bernstein; Mandy Busse; Hendrik Bielau; Ralf Brisch; Christian Mawrin; Susan Müller; Zoltán Sarnyai; Tomasz Gos; Bernhard Bogerts; Johann Steiner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-14       Impact factor: 5.270

Review 2.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Authors:  Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2011-12-29       Impact factor: 9.306

3.  The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.

Authors:  M K Yazici; A E Anil Yağcioğlu; A Ertuğrul; N Eni; S Karahan; E Karaağaoğlu; S L Tokgözoğlu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-06-03       Impact factor: 5.270

4.  Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan.

Authors:  Norio Sugawara; Norio Yasui-Furukori; Manabu Yamazaki; Kazutaka Shimoda; Takao Mori; Takuro Sugai; Hiroshi Matsuda; Yutaro Suzuki; Yuji Ozeki; Kurefu Okamoto; Toyoaki Sagae; Toshiyuki Someya
Journal:  Neuropsychiatr Dis Treat       Date:  2020-09-30       Impact factor: 2.570

5.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

6.  Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics?

Authors:  Esther Ching-Lan Lin; Wen-Chuan Shao; Hsin-Ju Yang; Miaofen Yen; Sheng-Yu Lee; Pei-Chun Wu; Ru-Band Lu
Journal:  Metab Brain Dis       Date:  2014-07-19       Impact factor: 3.584

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.